Puyskens A, Stinn A, van der Vaart M, Kreuchwig A, Protze J, Pei G, et al. Aryl Hydrocarbon Receptor Modulation by Tuberculosis Drugs Impairs Host Defense and Treatment Outcomes. Cell Host Microbe. 2020;27:238-248.e7 pubmed publisher

Xiao J, Rijal P, Schimanski L, Tharkeshwar A, Wright E, Annaert W, et al. Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein. J Virol. 2018;92: pubmed publisher

Arinto Garcia R, Pinho M, Carriço J, Melo Cristino J, Ramirez M. Comparing Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Phenotypic and Molecular Methods for Identification of Species within the Streptococcus anginosus Group. J Clin Microbiol. 2015;53:3580-8 pubmed publisher

Karavasilis V, Zarkotou O, Panopoulou M, Kachrimanidou M, Themeli Digalaki K, Stylianakis A, et al. Wide dissemination of linezolid-resistant Staphylococcus epidermidis in Greece is associated with a linezolid-dependent ST22 clone. J Antimicrob Chemother. 2015;70:1625-9 pubmed publisher

Mutters N, Werner G, Tacconelli E, Mischnik A. [Treatment options for serious infections caused by vancomycin-resistant enterococci]. Dtsch Med Wochenschr. 2015;140:42-5 pubmed publisher

Tian Y, Li T, Zhu Y, Wang B, Zou X, Li M. Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China. BMC Microbiol. 2014;14:292 pubmed publisher

Holland T, Arnold C, Fowler V. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014;312:1330-41 pubmed publisher

Usery J, Vo N, Finch C, Cleveland K, Gelfand M, Self T. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Am J Med Sci. 2015;349:36-41 pubmed publisher

Tacconelli E, Kern W. New antibiotics for skin and skin-structure infections. Lancet Infect Dis. 2014;14:659-661 pubmed publisher

Moran G, Fang E, Corey G, Das A, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14:696-705 pubmed publisher

Boucher H, Wilcox M, Talbot G, Puttagunta S, Das A, Dunne M. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169-79 pubmed publisher

Cağlayan K, Gungor B, Cinar H, Erdogan N, Koca B. Preventing intraperitoneal adhesions with linezolid and hyaluronic acid/carboxymethylcellulose: a comparative study in cecal abrasion model. Am J Surg. 2014;208:106-11 pubmed publisher

Yu Z, Chen Z, Cheng H, Zheng J, Li D, Deng X, et al. Complete genome sequencing and comparative analysis of the linezolid-resistant Enterococcus faecalis strain DENG1. Arch Microbiol. 2014;196:513-6 pubmed publisher

Drougka E, Foka A, Liakopoulos A, Doudoulakakis A, Jelastopulu E, Chini V, et al. A 12-year survey of methicillin-resistant Staphylococcus aureus infections in Greece: ST80-IV epidemic?. Clin Microbiol Infect. 2014;20:O796-803 pubmed publisher

Reznikov L, Abou Alaiwa M, Dohrn C, Gansemer N, Diekema D, Stoltz D, et al. Antibacterial properties of the CFTR potentiator ivacaftor. J Cyst Fibros. 2014;13:515-9 pubmed publisher

Oh C, Moon C, Park O, Kwon S, Jang J. Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model. J Antimicrob Chemother. 2014;69:1599-607 pubmed publisher

Brzychczy Wloch M, Borszewska Kornacka M, Gulczynska E, Wójkowska Mach J, Sulik M, Grzebyk M, et al. Prevalence of antibiotic resistance in multi-drug resistant coagulase-negative staphylococci isolated from invasive infection in very low birth weight neonates in two Polish NICUs. Ann Clin Microbiol Antimicrob. 2013;12:41 pubmed publisher

Roongruangpitayakul C, Chuchottaworn C. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand. J Med Assoc Thai. 2013;96:1273-82 pubmed

Sastre A, Roberts P, Presutti R. A practical guide to community-acquired MRSA. J Fam Pract. 2013;62:624-9 pubmed

Nie W, Chu N. [The analysis of clinical data about the treatment of linezolid against tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36:601-3 pubmed

Kraleti S, Soultanova I. Pancytopenia and lactic acidosis associated with linezolid use in a patient with empyema. J Ark Med Soc. 2013;110:62-3 pubmed

Sadeghi J, Mansouri S. Molecular characterization and antibiotic resistance of clinical isolates of methicillin-resistant Staphylococcus aureus obtained from Southeast of Iran (Kerman). APMIS. 2014;122:405-11 pubmed publisher

Saini J, Homeyer N, Fulle S, Gohlke H. Determinants of the species selectivity of oxazolidinone antibiotics targeting the large ribosomal subunit. Biol Chem. 2013;394:1529-41 pubmed publisher

Baietto L, D Avolio A, Ariaudo A, Corcione S, Simiele M, Cusato J, et al. Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;936:42-7 pubmed publisher

Yoo J, Lyu J, Lee S, Kim W, Kim D, Shim T. Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence]. Int J Tuberc Lung Dis. 2013;17:1243-4 pubmed publisher

Tsuji Y, Yukawa E, Hiraki Y, Matsumoto K, Mizoguchi A, Morita K, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J Clin Pharmacol. 2013;53:967-73 pubmed publisher

Whang D, Miller L, Partain N, McKinnell J. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother. 2013;57:5013-8 pubmed publisher

Shukla B, Gauthier T, Correa R, Smith L, Abbo L. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review. Int J Clin Pharm. 2013;35:697-703 pubmed publisher

Yue J, Dong B, Yang M, Chen X, Wu T, Liu G. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev. 2013;:CD008056 pubmed publisher

Moreno R, Rives S, Justicia A, Catala A, Ruiz Llobet A, Toll T, et al. Successful port-a-cath salvage using linezolid in children with acute leukemia. Pediatr Blood Cancer. 2013;60:E103-5 pubmed publisher

Helmy S. Pharmacokinetics and relative bioavailability evaluation of linezolid suspension and tablet formulations. Drug Res (Stuttg). 2013;63:489-94 pubmed publisher

González N, Sevillano D, Alou L, Cafini F, Gimenez M, Gómez Lus M, et al. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations rep. J Antimicrob Chemother. 2013;68:2291-5 pubmed publisher

Muzevich K, Lee K. Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother. 2013;47:e25 pubmed publisher

Thilesen C, Bjørang O, Skrede T, Aronsen T, Aasnaes B, Sundsfjord A, et al. Emergence of mutation-based linezolid-resistant invasive Enterococcus faecalis in a haemodialysis patient in Norway. APMIS. 2014;122:83-4 pubmed publisher

Różalski M, Micota B, Sadowska B, Paszkiewicz M, Wieckowska Szakiel M, Rozalska B. Antimicrobial/anti-biofilm activity of expired blood platelets and their released products. Postepy Hig Med Dosw (Online). 2013;67:321-5 pubmed

Jiang H, Tang R, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis. 2013;32:1121-8 pubmed publisher

Ramsey T, Lau T, Ensom M. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother. 2013;47:543-60 pubmed publisher

Diaz L, Kontoyiannis D, Panesso D, Albert N, Singh K, Tran T, et al. Dissecting the mechanisms of linezolid resistance in a Drosophila melanogaster infection model of Staphylococcus aureus. J Infect Dis. 2013;208:83-91 pubmed publisher

Diep B, Afasizheva A, Le H, Kajikawa O, Matute Bello G, Tkaczyk C, et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis. 2013;208:75-82 pubmed publisher

Fu J, Ye X, Chen C, Chen S. The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS ONE. 2013;8:e58240 pubmed publisher

Liu X, He Y, Xiao K, White J, Fusco D, Papanicolaou G. Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfection. PLoS ONE. 2013;8:e57483 pubmed publisher

Tu E, Jain S. Topical linezolid 0.2% for the treatment of vancomycin-resistant or vancomycin-intolerant gram-positive bacterial keratitis. Am J Ophthalmol. 2013;155:1095-1098.e1 pubmed publisher

Yang X, Chen Y, Yang Q, Qu T, Liu L, Wang H, et al. Emergence of cfr-harbouring coagulase-negative staphylococci among patients receiving linezolid therapy in two hospitals in China. J Med Microbiol. 2013;62:845-50 pubmed publisher

Cui L, Wang Y, Li Y, He T, Schwarz S, Ding Y, et al. Cfr-mediated linezolid-resistance among methicillin-resistant coagulase-negative staphylococci from infections of humans. PLoS ONE. 2013;8:e57096 pubmed publisher

Woytowish M, Maynor L. Clinical relevance of linezolid-associated serotonin toxicity. Ann Pharmacother. 2013;47:388-97 pubmed publisher

Chhibber S, Kaur T, Sandeep Kaur -. Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS ONE. 2013;8:e56022 pubmed publisher

Morata L, Cuesta M, Rojas J, Rodriguez S, Brunet M, Casals G, et al. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemother. 2013;57:1913-7 pubmed publisher

Wunderink R. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy?. Infect Dis Clin North Am. 2013;27:177-88 pubmed publisher

Gonzalez R, Rostas J, Simmons J, Allen J, Frotan M, Brevard S. Improved outcome of ventilator-associated pneumonia caused by methicillin-resistant Staphylococcus aureus in a trauma population. Am J Surg. 2013;205:255-8; discussion 258 pubmed publisher

Kojiro M, Tsuchihashi Y, Ishida M, Furumoto A, Matsuda J, Yanagihara K, et al. [A case of pacemaker-lead infection by linezolid-resistant methicillin-resistant Staphylococcus aureus in a hemodialysis patient]. Kansenshogaku Zasshi. 2012;86:778-83 pubmed

Cai Y, Chai D, Falagas M, Karageorgopoulos D, Wang R, Bai N, et al. Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study. Expert Opin Investig Drugs. 2013;22:309-15 pubmed publisher

Campanile F, Mongelli G, Bongiorno D, Adembri C, Ballardini M, Falcone M, et al. Worrisome trend of new multiple mechanisms of linezolid resistance in staphylococcal clones diffused in Italy. J Clin Microbiol. 2013;51:1256-9 pubmed publisher

Sarathy J, Dartois V, Dick T, Gengenbacher M. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57:1648-53 pubmed publisher

Lee D, Murakami Y, Andes D, Craig W. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother. 2013;57:1434-41 pubmed publisher

Raghunath A. Gingival pain: an unusual side effect of ziprasidone. BMJ Case Rep. 2013;2013: pubmed publisher

Ramirez E, Gómez Gil R, Borobia A, Moreno F, Zegarra C, Munoz R, et al. Improving linezolid use decreases the incidence of resistance among Gram-positive microorganisms. Int J Antimicrob Agents. 2013;41:174-8 pubmed publisher

Watkins R, Lemonovich T, File T. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid. 2012;7:131-43 pubmed publisher

Quiles Melero I, Gómez Gil R, Romero Gómez M, Sánchez Díaz A, De Pablos M, García Rodríguez J, et al. Mechanisms of linezolid resistance among Staphylococci in a tertiary hospital. J Clin Microbiol. 2013;51:998-1001 pubmed publisher

Matsumoto H, Kawabata R, Kishimoto T, Yamamoto E, Kimura Y, Imamura H, et al. [A case of refractory deep incisional surgical site infection due to methicillin-resistant Staphylococcus aureus (MRSA) and successfully treated with oral linezolid]. Gan To Kagaku Ryoho. 2012;39:2441-3 pubmed

Xu H, Xu C, Fan Z, Zhao L, Liu H. A facile synthesis, antibacterial activity of pulvinone and its derivatives. Bioorg Med Chem Lett. 2013;23:737-9 pubmed publisher

Descourouez J, Jorgenson M, Wergin J, Rose W. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother. 2013;57:1518-20 pubmed publisher

Szultka M, Krzeminski R, Szeliga J, Jackowski M, Buszewski B. A new approach for antibiotic drugs determination in human plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2013;1272:41-9 pubmed publisher

Bounthavong M, Hsu D. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections. Expert Rev Pharmacoecon Outcomes Res. 2012;12:683-98 pubmed publisher

Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries R. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013;68:4-11 pubmed publisher

He M, Jiang Y, Cai C. [Mechanisms and epidemiology of linezolid resistance in staphylococci]. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35:360-2 pubmed

Sotgiu G, Centis R, D Ambrosio L, Alffenaar J, Anger H, Caminero J, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430-42 pubmed publisher

Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16:447-54 pubmed publisher

Shen T, Wu L, Geng L, Wei Z, Zheng S. Successful treatment of pulmonary Nocardia farcinica infection with linezolid: case report and literature review. Braz J Infect Dis. 2011;15:486-9 pubmed

Long K, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother. 2012;56:603-12 pubmed publisher

Ross J, Farrell D, Mendes R, Sader H, Jones R. Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries. J Chemother. 2011;23:71-6 pubmed

Dryden M. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66 Suppl 4:iv7-iv15 pubmed publisher

Gould F. Linezolid: safety and efficacy in special populations. J Antimicrob Chemother. 2011;66 Suppl 4:iv3-iv6 pubmed publisher

Leach K, Brickner S, Noe M, Miller P. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci. 2011;1222:49-54 pubmed publisher

Ijzerman M, Tack K, Huang D. Combined retrospective analysis of seven phase II and III trials of the efficacy of linezolid in the treatment of pneumonia caused by multidrug-resistant Streptococcus pneumoniae. Clin Ther. 2010;32:2198-206 pubmed publisher